Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 87

  • 1 641 clinical trials
  • 555 recruiting
  • 290 conditions
  • 28 countries

Conditions in this area

290 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma88Dermatitis atopic88HIV infection75Rheumatoid arthritis75Systemic lupus erythematosus61Multiple sclerosis59Psoriasis53Psoriatic arthropathy46Myasthenia gravis43Systemic scleroderma39Type 1 diabetes mellitus38Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Cardiac amyloidosis29Sjogren's syndrome29Interstitial lung disease28Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy23Vitiligo23Hereditary angioedema22Axial spondyloarthritis21+266

Clinical trials in Immune system disorders

1 641 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 641 clinical trials

Psoriatic arthropathy

Not recruiting

Study on the Effectiveness and Safety of JNJ-77242113 for Patients with Active Psoriatic Arthritis Who Have Not Used Biologic Treatments

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Jnj-77242113
  • Sponsor:Janssen Cilag International

Chronic inflammatory demyelinating polyradiculoneuropathy

Not recruiting

Study on the Long-term Safety of Batoclimab for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Batoclimab
  • Sponsor:Immunovant Sciences GmbH

Cerebral amyloid angiopathy

Not recruiting

Study on the Safety and Effects of ALN-APP for Patients with Cerebral Amyloid Angiopathy

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:ALN-961583
  • Sponsor:Alnylam Pharmaceuticals Inc.

Interstitial lung disease+1

Not recruiting

Study to Test if Nerandomilast (BI 1015550) Helps Patients with Interstitial Lung Disease Related to Rheumatic Diseases

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:1-[[(5R)-2-[4-(5-Chloro-2-Pyrimidinyl)-1-Piperidinyl]-6,7- Dihydro-5-Oxidothieno[3,2-D]Pyrimidin-4- Yl]Amino]-Cyclobutanemethanol
  • Sponsor:Boehringer Ingelheim Espana S.A.

Conjunctivitis allergic+1

Not recruiting

Study on the Safety and Effectiveness of Subcutaneous Immunotherapy with Der p 1, Der p 2, and Der p 23 Allergens for Patients with Allergic Rhinitis or Rhinoconjunctivitis

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Dermatophagoides Pteronyssinus
  • Sponsor:Diater Laboratorio De Diagnostico Y Aplicaciones Terapeuticas S.A.

Conjunctivitis allergic+1

Not recruiting

Study on the Effectiveness and Safety of CLU-RX-DPT for Patients with Moderate-to-Severe House Dust Mite Allergy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Dermatophagoides Pteronyssinus Allergoid, Glutaraldehyde-Modified
  • Sponsor:ROXALL Medizin GmbH

Rheumatoid arthritis

Not recruiting

Study of Tocilizumab Subcutaneous Injection to Evaluate Bone Healing in Adult Patients with Rheumatoid Arthritis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tocilizumab
  • Sponsor:Centre Hospitalier Universitaire D Orleans

Ocular myasthenia

Not recruiting

Study on the Effectiveness and Safety of Efgartigimod in Adults with Ocular Myasthenia Gravis

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Crohn's disease

Not recruiting

Study of SAR441566 compared to placebo for adults with moderate to severe Crohn's disease

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Hereditary angioedema

Not recruiting

Study on NTLA-2002 for Treating Hereditary Angioedema in Patients: Evaluating the Effects of Ziclumeran and Lonvoguran

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lonvoguran
  • Sponsor:Intellia Therapeutics Inc.

Giant cell arteritis

Not recruiting

Study on the Effectiveness of Tocilizumab, Methylprednisolone, and Prednisone for Patients with Acute Anterior Ischemic Optic Neuropathy in Giant Cell Arteritis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Centre Hospitalier National D'Ophtalmologie Quinze-Vingts

Idiopathic pulmonary fibrosis

Not recruiting

Study on the Safety and Effectiveness of Taladegib for Patients with Idiopathic Pulmonary Fibrosis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:TALADEGIB
  • Sponsor:Endeavor Biomedicines Inc.

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine39 clinical trialsTocilizumab38 clinical trialsTenofovir Alafenamide37 clinical trialsMethotrexate36 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.